Browse

Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation

DC Field Value Language
dc.contributor.authorKim, Jin Seok-
dc.contributor.authorKim, Kihyun-
dc.contributor.authorCheong, June-Won-
dc.contributor.authorMin, Yoo Hong-
dc.contributor.authorKim, Hawk-
dc.contributor.authorRyoo, Hun Mo-
dc.contributor.authorLee, Joe Hoon-
dc.contributor.authorYoon, Sung Soo-
dc.contributor.authorJo, Deog Yeon-
dc.contributor.authorSuh, Cheolwon-
dc.date.accessioned2012-05-23T07:05:26Z-
dc.date.available2012-05-23T07:05:26Z-
dc.date.issued2009-04-
dc.identifier.citationBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION; Vol.15 4; 463-470ko_KR
dc.identifier.issn1083-8791-
dc.identifier.urihttps://hdl.handle.net/10371/76337-
dc.description.abstractUpfront high-dose myeloablative chemotherapy followed by a single autologous stem cell transplantation (ASCT) is the standard therapy for patients under the age of 65 years with newly diagnosed multiple myeloma (MM). Because disease status after induction chemotherapy is variable, we evaluated the prognostic effect of disease status before ASCT especially in patients who were initially chemosensitive. We retrospectively analyzed the initially chemosensitive MM patients (>= partial remission [PR]) enrolled in the Korean Multiple Myeloma Working Party Web-based registration system (www.myeloma.or.kr), Between November 1996 and January 2007, 197 MM patients (median age 53 years) were treated with induction chemotherapy followed by a single ASCT All patients received peripheral blood stem cell (PBSC) support after conditioning with mel-Phalan (Mel) alone. We considered those patients with no detectable M-protein regardless of the result of immunofixation to be in complete remission (CR) in this study. The median follow-up times were 29.2 months (range, 5.4 to 103.8 months) from the day of diagnosis and 22.4 months (range, 0.4 to 96.0 months) from the day of ASCT Before ASCT, 63 patients (32%) were in CR and 134 (68%) were in partial remission (PR). The patients in CR had significantly longer overall survival (OS) from the day of ASCT compared with those in PR (P = .0015). Among the patients who received induction chemotherapy with vincristine, adriamycin, and dexamethasone (n = 162), the same difference in OS was seen between those in CR and those in PR before ASCT (P = .0016). CR after ASCT also predicted longer OS (P = .0135); however, patients with continued CR after ASCT had significantly higher OS after ASCT compared with patient with induced CR after ASCT who were in PR before ASCT (P = .0178). Multivariate analysis indicated that remission status pre-ASCT (CR vs PR) is a significant prognostic factor for predicting OS after ASCT (P = .012, Cox proportional hazard analysis; odds ratio = 2.83; 95% confidence interval = 1.25 to 6.37). We conclude that patients with MM who are in CR before ASCT have a better OS than those in PR before ASCT Continued CR after ASCT may be an important prognostic factor as well. Our findings suggest that the development of more effective induction regimens, including novel antimyeloma agents to improve initial response, should be pursued to enhance clinical benefits post-ASCT.ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCIENCE INCko_KR
dc.subjectMultiple myelomako_KR
dc.subjectAutologous stem cell transplantationko_KR
dc.subjectOverall survivalko_KR
dc.subjectPrognostic factorko_KR
dc.subjectComplete remissionko_KR
dc.titleComplete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김진석-
dc.contributor.AlternativeAuthor김기현-
dc.contributor.AlternativeAuthor정준원-
dc.contributor.AlternativeAuthor민유홍-
dc.contributor.AlternativeAuthor서철원-
dc.contributor.AlternativeAuthor김학-
dc.contributor.AlternativeAuthor조덕연-
dc.contributor.AlternativeAuthor류훈모-
dc.contributor.AlternativeAuthor윤성수-
dc.contributor.AlternativeAuthor이조훈-
dc.identifier.doi10.1016/j.bbmt.2008.12.512-
dc.citation.journaltitleBIOLOGY OF BLOOD AND MARROW TRANSPLANTATION-
dc.description.citedreferenceLudwig H, 2008, BLOOD, V111, P4039, DOI 10.1182/blood-2007-03-081018-
dc.description.citedreferenceKyle RA, 2008, BLOOD, V111, P2962-
dc.description.citedreferenceKumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129-
dc.description.citedreferenceBrenner H, 2008, BLOOD, V111, P2521, DOI 10.1182/blood-2007-08-104984-
dc.description.citedreferenceMehta J, 2007, BONE MARROW TRANSPL, V40, P1101, DOI 10.1038/sj.bmt.1705799-
dc.description.citedreferenceLacy MQ, 2007, MAYO CLIN PROC, V82, P1179-
dc.description.citedreferenceHAROUSSEAU JL, 2007, BLOOD, V110, P139-
dc.description.citedreferenceCAVO M, 2007, BLOOD, V110, P30-
dc.description.citedreferenceHarousseau JL, 2006, HAEMATOL-HEMATOL J, V91, P1498-
dc.description.citedreferenceBarlogie B, 2006, BRIT J HAEMATOL, V135, P158, DOI 10.1111/j.1365-2141.2006.06271.x-
dc.description.citedreferenceKim H, 2006, BIOL BLOOD MARROW TR, V12, P837, DOI 10.1016/j.bbmt.2006.04.006-
dc.description.citedreferenceO`Shea D, 2006, BONE MARROW TRANSPL, V37, P731, DOI 10.1038/sj.bmt.1705307-
dc.description.citedreferenceRajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221-
dc.description.citedreferenceHari P, 2006, BONE MARROW TRANSPL, V37, P1, DOI 10.1038/sj.bmt.1705194-
dc.description.citedreferenceCavo M, 2005, BLOOD, V106, P35-
dc.description.citedreferenceGreipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242-
dc.description.citedreferenceKyle RA, 2004, NEW ENGL J MED, V351, P1860-
dc.description.citedreferenceKumar S, 2004, BONE MARROW TRANSPL, V34, P161, DOI 10.1038/sj.bmt.1704545-
dc.description.citedreferenceTRICOT G, 2004, BLOOD, V104, P936-
dc.description.citedreferenceAttal M, 2003, NEW ENGL J MED, V349, P2495-
dc.description.citedreferenceSinghal S, 2002, BONE MARROW TRANSPL, V30, P673, DOI 10.1038/sj.bmt.1703717-
dc.description.citedreferenceBLADE J, 1998, BRIT J HAEMATOL, V102, P1115-
dc.description.citedreferenceBarlogie B, 1997, BLOOD, V89, P789-
dc.description.tc9-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse